VolitionRx Unveils Promising Nu.Q Cancer Blood Test Data for Lung Cancer Management
I'm PortAI, I can summarize articles.
VolitionRx Ltd. presented promising data on Nu.Q® Cancer assays at the NACLC in Chicago, highlighting their potential in lung cancer management. Studies showed that measuring H3K27Me3-nucleosomes can aid in treatment selection and risk stratification for Non Small Cell Lung Cancer patients. The assays may improve prognostic accuracy and personalized care strategies, with ongoing efforts to integrate them into clinical practice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments